SCHEMBL427956

SCHEMBL427956

COc1cccc(-c2cn(C(=O)N3COCC3(C)C)cn2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
PLK1 P53350 1/20 0.39
BACE1 P56817 2/20 0.39
IKBKB O14920 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
WDR5 P61964 1/20 0.37
KCNH2 Q12809 1/20 0.37
FYN P06241 1/20 0.37
STIM1 Q13586 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427620 0.88 KDM4E (0.38) TP53MAPTGAANPC1RAB9A
SCHEMBL427485 0.86 FAAH (0.38) GAARAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL427643 0.86 HSD17B1 (0.37) TP53GAANPC1RAB9ASMN1; SMN2
SCHEMBL7898244 0.86 KMO (0.38) TP53MAPTGAANPC1RAB9A
SCHEMBL425743 0.86 FAAH (0.43) GAARAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL427475 0.84 CNR2 (0.38) TP53MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL426083 0.84 KDM4E (0.47) TP53BACE1NPC1RAB9AALDH1A1
SCHEMBL427975 0.84 CYP11B1 (0.37) BACE1KCNH2KDM4E
SCHEMBL428071 0.84 BACE1 (0.47) TP53GAABACE1SMN1; SMN2ALDH1A1
SCHEMBL424813 0.83 CNR2 (0.41) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 TP53 4604/4885MAPT 1705/4885GAA 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.